arrow
L

Lapo Alinari

Ohio State University
H指数:38
被引数:5,235

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Spatial tissue analysis of secondary sarcoma following CAR T cell therapy for B cell lymphoma

B细胞淋巴瘤CAR T细胞疗法后继发性肉瘤的空间组织分析

2026-07-010
PRE
Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate

非霍奇金淋巴瘤患者接受大剂量甲氨蝶呤治疗时与末相甲氨蝶呤清除率相关的临床特征

2026-02-010
PRE
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma

I/II期研究:Subasumstat(TAK-981)联合利妥昔单抗治疗复发/难治性非霍奇金淋巴瘤

2025-05-030
OAAI
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

血液恶性肿瘤患者接受CAR T细胞疗法后的第二原发恶性肿瘤

2025-03-180
OA
Tumor Microenvironment-Induced Interleukin-6 Regulates Proliferation and Survival in Patients with Mantle Cell Lymphoma (MCL) By Activating FGFR1 Signaling

肿瘤微环境诱导的白细胞介素-6通过激活FGFR1信号通路调节套细胞淋巴瘤(MCL)患者的增殖和存活

BLOOD
IF23.1
2024-11-050
PRE
Transcriptomic Analysis in Mantle Cell Lymphoma Patients Identified MALAT1 Long-Non-Coding RNA to Regulate Cell Cycle Progression By Modulating EZH2/p57/Sox11 Axis

转录组分析在套细胞淋巴瘤患者中鉴定出MALAT1长非编码RNA,可通过调节EZH2/p57/Sox11轴来调控细胞周期进程

BLOOD
IF23.1
2024-11-050
PRE
Postinfusion PD-1+CD8+CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
2024-06-131
OAAI
Resistance to PRMT5-targeted therapy in mantle cell lymphoma
2023-12-292
OAAI
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
2023-10-133
OAAI
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma
LEUKEMIA
IF13.4
2023-08-196
OAAI